See more : Yotta Acquisition Corporation (YOTAR) Income Statement Analysis – Financial Results
Complete financial analysis of Heron Therapeutics, Inc. (HRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rentokil Initial plc (RKLIF) Income Statement Analysis – Financial Results
- CRH plc (CRHCF) Income Statement Analysis – Financial Results
- Daphne International Holdings Limited (DPNEY) Income Statement Analysis – Financial Results
- Astral Foods Limited (ARL.JO) Income Statement Analysis – Financial Results
- NH Hotel Group, S.A. (NHHEF) Income Statement Analysis – Financial Results
Heron Therapeutics, Inc. (HRTX)
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.04M | 107.67M | 86.35M | 88.64M | 145.97M | 77.47M | 30.77M | 1.28M | 0.00 | 0.00 | 0.00 | 0.00 | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.82M | 4.39M | 3.37M | 20.40M | 20.00M | 18.30M | 18.70M | 16.10M | 15.90M | 19.90M | 7.30M | 2.80M | 2.40M | 2.80M | 2.50M | 1.70M |
| Cost of Revenue | 65.11M | 54.87M | 46.02M | 36.19M | 61.62M | 27.51M | 4.59M | 35.00K | 734.00K | 54.83M | 30.92M | 14.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 445.00K | 440.27K | 613.20K | 6.40M | 5.70M | 6.00M | 9.40M | 9.80M | 9.00M | 11.60M | 3.80M | 1.10M | 1.20M | 700.00K | 600.00K | 400.00K |
| Gross Profit | 61.94M | 52.80M | 40.33M | 52.45M | 84.35M | 49.96M | 26.18M | 1.24M | -734.00K | -54.83M | -30.92M | -14.08M | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.37M | 3.95M | 2.75M | 14.00M | 14.30M | 12.30M | 9.30M | 6.30M | 6.90M | 8.30M | 3.50M | 1.70M | 1.20M | 2.10M | 1.90M | 1.30M |
| Gross Profit Ratio | 48.75% | 49.04% | 46.70% | 59.17% | 57.79% | 64.49% | 85.09% | 97.26% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 92.35% | 89.96% | 81.78% | 68.63% | 71.50% | 67.21% | 49.73% | 39.13% | 43.40% | 41.71% | 47.95% | 60.71% | 50.00% | 75.00% | 76.00% | 76.47% |
| Research & Development | 55.90M | 107.51M | 130.82M | 174.53M | 167.38M | 140.03M | 138.58M | 103.13M | 61.18M | 54.83M | 32.78M | 15.05M | 8.21M | 7.26M | 7.80M | 19.51M | 19.36M | 15.24M | 10.30M | 11.50M | 8.66M | 6.70M | 7.35M | 3.71M | 4.30M | 4.40M | 3.70M | 3.50M | 4.10M | 6.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 49.01M | 37.44M | 40.15M | 42.23M | 37.90M | 29.26M | 25.55M | 21.37M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 67.64M | 82.51M | 87.18M | 63.85M | 89.76M | 64.60M | 56.60M | 47.67M | 17.35M | 8.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.66M | 119.95M | 127.33M | 106.08M | 127.66M | 93.87M | 82.16M | 69.03M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 8.50M | 17.50M | 8.80M | 4.90M | 5.10M | 6.70M | 6.90M | 4.50M |
| Other Expenses | 0.00 | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -38.00K | -2.23M | -666.00K | -1.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| Operating Expenses | 172.55M | 227.46M | 258.15M | 280.61M | 295.04M | 233.90M | 220.74M | 172.16M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.19M | 10.65M | 7.06M | 11.30M | 11.80M | 12.30M | 16.30M | 14.90M | 15.90M | 18.70M | 9.90M | 5.70M | 5.90M | 7.40M | 7.80M | 5.40M |
| Cost & Expenses | 237.66M | 282.33M | 304.17M | 316.80M | 356.66M | 261.41M | 225.33M | 172.19M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.64M | 11.09M | 7.67M | 17.70M | 17.50M | 18.30M | 25.70M | 24.70M | 24.90M | 30.30M | 13.70M | 6.80M | 7.10M | 8.10M | 8.40M | 5.80M |
| Interest Income | 3.36M | 1.64M | 433.00K | 3.63M | 7.26M | 5.97M | 1.05M | 445.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 587.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.87M | 2.47M | 2.41M | 1.90M | 1.47M | 2.67M | 3.94M | 2.66M | 958.00K | 887.00K | 826.00K | 599.00K | 373.00K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.90M | 2.89M | 3.02M | 2.85M | 2.04M | 1.51M | 1.53M | 1.10M | 734.00K | 578.00K | 333.00K | 197.00K | 179.00K | 227.00K | 356.00K | 412.00K | 289.00K | -244.00K | 446.00K | 314.00K | 460.00K | 482.00K | 406.06K | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| EBITDA | -103.79M | -176.66M | -215.25M | -222.53M | -201.23M | -174.66M | -192.02M | -169.38M | -96.19M | -73.98M | -54.46M | -23.83M | -10.88M | -6.97M | -9.86M | -22.51M | -19.44M | 5.91M | -8.03M | -9.02M | -5.96M | -4.58M | -6.77M | -4.03M | -1.50M | -2.00M | -800.00K | -7.10M | -7.40M | -7.90M | -9.20M | -5.30M | -3.20M | -3.90M | -4.60M | -5.00M | -3.20M |
| EBITDA Ratio | -81.70% | -162.21% | -252.27% | -257.41% | -142.94% | -237.42% | -624.10% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,684.67% | -956.73% | -783.58% | -6,223.85% | -6,274.51% | 0.00% | -148.95% | -166.99% | -130.05% | -75.84% | -145.49% | -132.20% | 15.69% | 18.50% | 4.92% | -24.06% | -44.72% | -47.80% | -50.75% | -83.56% | -128.57% | -204.17% | -196.43% | -244.00% | -217.65% |
| Operating Income | -110.62M | -174.66M | -217.83M | -228.16M | -210.69M | -183.94M | -194.56M | -170.92M | -96.93M | -74.56M | -54.46M | -23.83M | -11.06M | -9.93M | -10.24M | -23.45M | -23.63M | -18.86M | -8.47M | -9.32M | -6.61M | -4.82M | -6.70M | -4.31M | 2.70M | 2.50M | -300.00K | -7.00M | -8.60M | -9.00M | -10.40M | -6.40M | -4.00M | -4.70M | -5.30M | -5.90M | -4.10M |
| Operating Income Ratio | -87.07% | -162.21% | -252.27% | -257.41% | -144.34% | -237.42% | -632.36% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,712.38% | -763.57% | -812.21% | -6,353.66% | -5,736.17% | 0.00% | -157.17% | -172.39% | -136.39% | -82.96% | -152.79% | -127.96% | 13.24% | 12.50% | -1.64% | -37.43% | -53.42% | -56.60% | -52.26% | -87.67% | -142.86% | -195.83% | -189.29% | -236.00% | -241.18% |
| Total Other Income/Expenses | 56.00K | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -2.93M | -2.23M | -666.00K | -1.81M | -826.00K | -599.00K | -373.00K | 2.74M | 24.00K | 520.00K | 3.83M | 24.38M | 290.00K | 224.00K | 153.00K | 297.00K | 712.64K | 26.39K | 0.00 | 200.00K | 300.00K | 400.00K | -200.00K | -300.00K | 900.00K | 600.00K | 0.00 | 1.00M | 900.00K | 1.10M | 500.00K |
| Income Before Tax | -110.56M | -182.02M | -220.68M | -227.28M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -24.43M | -11.44M | -7.20M | -10.15M | -23.13M | -19.80M | 5.52M | -8.47M | -9.29M | -6.46M | -4.76M | -6.62M | -4.28M | 0.00 | 2.70M | 0.00 | -8.10M | -8.80M | -9.30M | -9.50M | -5.80M | -4.00M | -3.70M | -4.40M | -4.80M | -3.60M |
| Income Before Tax Ratio | -87.02% | -169.05% | -255.58% | -256.41% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,770.12% | -553.11% | -804.92% | -6,266.94% | -4,805.83% | 0.00% | -157.11% | -171.98% | -133.23% | -81.79% | -150.83% | -127.18% | 0.00% | 13.50% | 0.00% | -43.32% | -54.66% | -58.49% | -47.74% | -79.45% | -142.86% | -154.17% | -157.14% | -192.00% | -211.76% |
| Income Tax Expense | 0.00 | -47.51M | -3.02M | -2.85M | 1.87M | 7.77M | 3.90M | -1.10M | -734.00K | -578.00K | -333.00K | -1.28M | 379.00K | -2.59M | -122.00K | -320.00K | 41.00K | 119.00K | -263.00K | -95.00K | -2.25M | -1.05M | -4.19M | -12.86M | 300.00K | 600.00K | 700.00K | 2.40M | 800.00K | 800.00K | -500.00K | -200.00K | 300.00K | -800.00K | -800.00K | -900.00K | -300.00K |
| Net Income | -110.56M | -134.52M | -217.66M | -224.43M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -23.35M | -11.81M | -7.35M | -10.03M | -23.13M | -20.16M | 5.27M | -8.21M | -9.22M | -4.36M | -3.78M | -2.51M | 8.55M | 2.40M | 1.90M | -700.00K | -9.40M | -9.40M | -9.80M | -9.90M | -5.60M | -4.30M | -3.90M | -4.50M | -5.00M | -3.80M |
| Net Income Ratio | -87.02% | -124.93% | -252.08% | -253.20% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,828.79% | -564.64% | -795.24% | -6,266.94% | -4,893.93% | 0.00% | -152.29% | -170.63% | -90.00% | -64.97% | -57.29% | 254.09% | 11.76% | 9.50% | -3.83% | -50.27% | -58.39% | -61.64% | -49.75% | -76.71% | -153.57% | -162.50% | -160.71% | -200.00% | -223.53% |
| EPS | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.70 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 10.40 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| EPS Diluted | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.25 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 9.60 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| Weighted Avg Shares Out | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 78.95K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.24K | 250.99K | 248.18K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
| Weighted Avg Shares Out (Dil) | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 79.49K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.43K | 253.15K | 254.76K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
Relief For Heron Therapeutics After The Court Win On Cinvanti
Heron Therapeutics won a court case securing Cinvanti's patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on growing the business. Heron missed Q3 revenue estimates, but...
U.S. District Court Upholds Validity of CINVANTI® Patents
— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that...
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President & Chief Financial Officer William...
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago...
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track...
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy,...
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
SAN DIEGO , Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at...
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
SAN DIEGO , Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced...
Source: https://incomestatements.info
Category: Stock Reports